PRTG
Price:
$4.62
Market Cap:
$4.85M
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses o...[Read more]
Industry
Biotechnology
IPO Date
2002-01-02
Stock Exchange
NASDAQ
Ticker
PRTG
According to Portage Biotech Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.55M. This represents a change of -99.64% compared to the average of 435.10M of the last 4 quarters.
The mean historical Enterprise Value of Portage Biotech Inc. over the last ten years is 1.48B. The current 1.55M Enterprise Value has changed -89.52% with respect to the historical average. Over the past ten years (40 quarters), PRTG's Enterprise Value was at its highest in in the March 2021 quarter at 6.73B. The Enterprise Value was at its lowest in in the June 2024 quarter at 811.16K.
Average
1.48B
Median
934.53M
Minimum
219.98M
Maximum
6.56B
Discovering the peaks and valleys of Portage Biotech Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 229.07%
Maximum Annual Enterprise Value = 6.56B
Minimum Annual Increase = -77.68%
Minimum Annual Enterprise Value = 219.98M
Year | Enterprise Value | Change |
---|---|---|
2024 | 219.98M | -77.68% |
2023 | 985.61M | -41.77% |
2022 | 1.69B | -74.20% |
2021 | 6.56B | 229.07% |
2020 | 1.99B | 120.64% |
2019 | 903.63M | 114.54% |
2018 | 421.19M | -56.37% |
2017 | 965.42M | 69.16% |
2016 | 570.70M | 23.38% |
2015 | 462.54M | 19.71% |
The current Enterprise Value of Portage Biotech Inc. (PRTG) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
966.11M
5-year avg
2.29B
10-year avg
1.48B
Portage Biotech Inc.’s Enterprise Value is less than Amylyx Pharmaceuticals, Inc. (291.98M), less than Karuna Therapeutics, Inc. (12.43B), less than Blueprint Medicines Corporation (6.36B), less than Arvinas, Inc. (1.69B), less than Aerovate Therapeutics, Inc. (46.23M), less than Eliem Therapeutics, Inc. (119.64M), less than Anebulo Pharmaceuticals, Inc. (36.46M), less than Cue Biopharma, Inc. (41.71M), less than Decibel Therapeutics, Inc. (102.82M), less than Keros Therapeutics, Inc. (1.75B), less than Janux Therapeutics, Inc. (2.64B), less than Fennec Pharmaceuticals Inc. (105.60M), less than Edgewise Therapeutics, Inc. (3.01B), less than Harmony Biosciences Holdings, Inc. (1.74B), less than Lineage Cell Therapeutics, Inc. (70.15M), less than MAIA Biotechnology, Inc. (41.04M), less than Armata Pharmaceuticals, Inc. (138.55M), greater than Frequency Therapeutics, Inc. (-29354368.00), less than Day One Biopharmaceuticals, Inc. (963.46M), less than Acumen Pharmaceuticals, Inc. (139.19M), less than X4 Pharmaceuticals, Inc. (38.44M), less than Inozyme Pharma, Inc. (202.73M), less than VectivBio Holding AG (848.58M),
Company | Enterprise Value | Market cap |
---|---|---|
291.98M | $361.25M | |
12.43B | $12.60B | |
6.36B | $5.98B | |
1.69B | $1.78B | |
46.23M | $76.81M | |
119.64M | $342.68M | |
36.46M | $37.86M | |
41.71M | $64.62M | |
102.82M | $123.37M | |
1.75B | $2.27B | |
2.64B | $2.64B | |
105.60M | $145.92M | |
3.01B | $3.05B | |
1.74B | $1.94B | |
70.15M | $95.15M | |
41.04M | $49.73M | |
138.55M | $81.41M | |
-29354368.00 | $10.94M | |
963.46M | $1.38B | |
139.19M | $142.39M | |
38.44M | $57.64M | |
202.73M | $180.51M | |
848.58M | $1.06B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Portage Biotech Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Portage Biotech Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Portage Biotech Inc.'s Enterprise Value?
What is the highest Enterprise Value for Portage Biotech Inc. (PRTG)?
What is the 3-year average Enterprise Value for Portage Biotech Inc. (PRTG)?
What is the 5-year average Enterprise Value for Portage Biotech Inc. (PRTG)?
How does the current Enterprise Value for Portage Biotech Inc. (PRTG) compare to its historical average?